Oncology & Hematology

Accelerate oncology breakthroughs.

Clinical development of hematology and oncology therapies have rapidly advanced. Novel therapies bring the promise of better outcomes for patients. But new discoveries come with a more complex development path. IQVIA experts are here to help support your hematology or oncology trials, helping you bring new therapies to waiting patients faster.

 

 

 

Advancing Drug Development Together to Make Breakthrough Therapies a Reality for Patients

Your scientific breakthroughs deserve a new approach to development

By making intelligent connections, we bring innovation to the needs of today’s oncology development to help you focus on the patient, manage trial complexity, and increase predictability and speed. IQVIA helps you

  • Integrate biomarker strategies, operations and partners from development plans through trial execution
  • Design and execute adaptive and novel trial designs
  • Use patient insights to improve trial design, speed recruitment and reduce patient burden
  • Plan and execute cell and gene therapy programs with specialized expertise and resources 
  • Optimize development plans by applying real world and commercial insights in clinical strategies and forecasting scenarios
  • Apply AI and machine learning to improve trial efficiency and patient safety

Early phase oncology

Oncology drug development is shifting from a drug-centered approach to a patient-centered one. In the realm of oncology therapeutics, from dose escalation through dose optimization, IQVIA’s teams are here to help you navigate the evolving landscape and make informed decisions quickly.

  • 690+ Phase I-II studies since 2016
  • Dedicated clinical and operational experts for trial design strategy and execution
  • Technology solutions for enhanced cohort planning and management
  • Established global network of qualified Phase I oncology sites working in close alignment for fast site activation and better patient recruitment
  • Modeling and simulation of multiple datasets to identify optimal dose of targeted therapies
  • End to end laboratory services from IQVIA Laboratories for biomarker services, assay validation and development of companion diagnostics

Leader in Hematology and Oncology Clinical Development

GLOBAL EXPERIENCE
46

Regulatory approvals (FDA, PMDA, MHRA, EC) across 14 indications in oncology from 2020 - 2023

ONCOLOGY DRUGS
84%

Of FDA approved oncology drugs between 2016 – 2023 involved IQVIA

HEMATOLOGY DRUGS
94%

Of FDA approved hematology drugs between 2016 – 2023 involved IQVIA

Leverage the power of real world oncology data

Through advanced analytics, such as artificial intelligence and machine learning, coupled with our oncology expertise, IQVIA Oncology Commercial Solutions can help track the impact of clinical advancements in real world diagnosis and treatment patterns. By accelerating time to insights we help customers drive business decisions which, ultimately, impact patient care. 
Explore our collection of hematology and oncology insights
Latest hematology and oncology clinical research trends and perspectives from IQVIA experts for successful drug development

Therapeutic expertise — hands-on and hand-selected for biotech

Therapeutically aligned solutions to advance your clinical program to the next milestone.

Related solutions

Explore More

Contact Us